Valuing innovative endoscopic techniques: prophylactic clip closure after endoscopic resection of large colon polyps - 19/05/20
Abstract |
Background and Aims |
Clip closure of the mucosal defect after resecting large (≥20 mm) nonpedunculated colorectal polyps reduces postprocedure bleeding and is cost saving for payers. Clip costs are not reimbursed by payers, posing a major barrier to adoption of this technique in the community. We aimed to determine appropriate clip costs to support broader use of this procedure in practice.
Methods |
We performed budget impact analysis using our recent decision analytic model, comparing prophylactic clip closure with no clip closure on national cost and outcomes data, to determine the maximum feasible clip price while maintaining cost savings in practice. Sensitivity analyses were performed on important clinical factors.
Results |
In the original model, the baseline postprocedure bleeding risk was 6.8%, increasing cost of care by $614.11 averaged among all patients undergoing large polyp resection without clip closure. Prophylactic clip closure of only large right-sided polyps reduced postprocedure bleeding risk by 70.7% but resulted in cost saving only if the price of clips was $100 or less. Comparatively, prophylactic clip closure of large left-sided polyps had no clinical benefit and was not cost saving. Clip closure strategies focused only on extra-large polyps (≥40 mm), or patients taking antithrombotics regardless of polyp characteristics, were only minimally cost saving. Cost savings and maximum tolerated clip prices depended on medical comorbidity, which directly influences the costs of care to manage postprocedure bleeding.
Conclusions |
Prophylactic clip closure after endoscopic resection of large colon polyps, particularly those in the right colon segment, is cost saving but requires clip costs less than $100. Translating these findings into practice requires gastroenterology practices to obtain reimbursement from payers for improved clinical outcomes and to align commercial clip prices with this clinical indication.
Il testo completo di questo articolo è disponibile in PDF.Abbreviations : CI, CMS
Mappa
| DISCLOSURE: Dr Law was a consultant for Olympus America and received royalties from UpToDate. Dr Rex was a consultant for Olympus Corporation, Boston Scientific, Medtronic, Aries, Braintree Laboratories; received research support from EndoAid, Olympus Corporation, Medivators, Erbe USA; and has ownership in Satisfai Health. Dr Pohl received research grants from Boston Scientific, US Endoscopy, and Aries Pharmaceuticals. Dr Feagins, sponsored clinical research trial with Corona, Inc. Dr Crockett, clinical trial agreements/research support from Freenome, Guardant Health, Exact Sciences, ColoWrap; consulting for IngenioRx; general payments/minor food and beverage from Ferring Pharmaceuticals, Salix Pharmaceuticals, and Boston Scientific. Dr Wallace consulted for Virgo Inc, Cosmo/Aries Pharmaceuticals, Anx Robotica, Covidien; obtained research grants from Fujifilm, Boston Scientific, Olympus, Medtronic, Ninepoint Medical, Cosmo/Aries Pharmaceuticals; held stock options in Virgo, Inc; consulted on behalf of Mayo Clinic for GI Supply (2018), Endokey, Endostart, Boston Scientific, MicroTek; received general payments/minor food and beverages from Synergy Pharmaceuticals, Boston Scientific, Cook Medical. All other authors disclosed no financial relationships relevant to this publication. |
|
| See CME section; p. 1378. |
Vol 91 - N° 6
P. 1353-1360 - giugno 2020 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
